Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
ApexOnco Front Page
Recent articles
11 June 2025
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
10 June 2025
AVZO-023 follows AVZO-021 into clinical trials.
9 June 2025
The move follows promising but early data presented at ASCO.
9 June 2025
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
9 June 2025
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
6 June 2025
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.